News Releases

Date	Title and Summary	View
Mar 17, 2023	TREMFYA® (guselkumab) Real-World Data Analyses Show Greater Treatment Persistence Than IL-17s in Both Bio-naïve and Bio-experienced Patients Living With Moderate to Severe Plaque Psoriasis
Mar 15, 2023	Johnson & Johnson to Host Investor Conference Call on First-Quarter Results NEW BRUNSWICK, N.J. --(BUSINESS WIRE)--Mar. 15, 2023-- Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 18 th to review first-quarter results. Joseph J. Wolk , Executive Vice President and Chief Financial Officer and Jessica
Mar 06, 2023	Late-Breaking Phase 3 A DUE Data Show Investigational Single Tablet Combination Therapy of Macitentan and Tadalafil Significantly Improves Pulmonary Hemodynamics versus Monotherapy in Patients with Pulmonary Arterial Hypertension (PAH)
Mar 04, 2023	New STELARA® (ustekinumab) Long-Term Data Support its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative Colitis
Mar 03, 2023	TREMFYA® (guselkumab) Demonstrates a Differentiated Binding Mechanism from Risankizumab in In Vitro Studies
Feb 28, 2023	Janssen Submits New Drug Application to the U.S. Food and Drug Administration Seeking Approval of Niraparib and Abiraterone Acetate Dual-Action Tablet, Plus Prednisone, as a First-Line Targeted Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer with BRCA Gene Mutations
Feb 24, 2023	Janssen Receives Positive CHMP Opinion for AKEEGA® (Niraparib and Abiraterone Acetate Dual Action Tablet) Plus Prednisone or Prednisolone for the Treatment of Adult Patients with BRCA1/2 Gene-Mutated Metastatic Castration Resistant Prostate Cancer
Feb 16, 2023	Janssen Presents Updated Data Demonstrating Improved Outcomes from the Use of Niraparib in Combination with Abiraterone Acetate Plus Prednisone as a First-Line Therapy in Patients with BRCA-Positive Metastatic Castration - Resistant Prostate Cancer
Feb 14, 2023	Johnson & Johnson to Participate in the Barclays Global HealthCare Conference
Feb 13, 2023	Johnson & Johnson Appoints Dr. John Reed as Executive Vice President, Pharmaceuticals, R&D